WallStreetZenWallStreetZen

NASDAQ: ARWR
Arrowhead Pharmaceuticals Inc Stock Ownership - Who owns Arrowhead Pharmaceuticals?

Insider buying vs selling

Have Arrowhead Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Victoria VakienerDirector2024-05-021,799$23.31
$41.93kSell
James C. HamiltonChief DiscoveryTrans Medicine2024-04-016,000$28.03
$168.18kSell
Hongbo LuDirector2024-03-201,000$27.50
$27.50kBuy
Hongbo LuDirector2024-03-191,000$28.00
$28.00kBuy
Hongbo LuDirector2024-03-181,000$27.49
$27.49kBuy
Kenneth Allen MyszkowskiChief Financial Officer2024-03-0640,000$35.19
$1.41MSell
Christopher Richard AnzaloneChief Executive Officer2024-01-3119,730$32.71
$645.37kSell
Christopher Richard AnzaloneChief Executive Officer2024-01-3137,769$32.16
$1.21MSell
Christopher Richard AnzaloneChief Executive Officer2024-01-3157,499$14.54
$836.04kBuy
James C. HamiltonChief DiscoveryTrans Medicine2024-01-123,702$37.37
$138.34kSell

1 of 6

ARWR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ARWR insiders and whales buy or sell their stock.

ARWR Shareholders

What type of owners hold Arrowhead Pharmaceuticals Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Blackrock Inc12.36%15,346,637$384.28MInstitution
Vanguard Group Inc9.99%12,404,050$310.60MInstitution
Avoro Capital Advisors LLC6.89%8,555,555$214.23MInstitution
State Street Corp5.28%6,560,703$164.28MInstitution
Fmr LLC5.15%6,394,628$160.12MInstitution
David M. Knott4.52%5,609,690$140.47MInsider
Slate Path Capital LP3.33%4,139,000$103.64MInstitution
Christopher Richard Anzalone2.99%3,715,048$93.02MInsider
Artal Group Sa2.44%3,036,668$76.04MInstitution
Geode Capital Management LLC2.22%2,754,634$68.98MInstitution

1 of 3

ARWR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ARWR76.41%10.68%Net SellingNet Selling
APGE89.97%10.03%Net Buying
IDYA91.35%8.65%Net SellingNet Buying
XENE96.73%3.27%Net SellingNet Selling
SMMT7.06%92.92%Net BuyingNet Buying

Arrowhead Pharmaceuticals Stock Ownership FAQ

Who owns Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is owned by 76.41% institutional shareholders, 10.68% Arrowhead Pharmaceuticals insiders, and 12.91% retail investors. David M. Knott is the largest individual Arrowhead Pharmaceuticals shareholder, owning 5.61M shares representing 4.52% of the company. David M. Knott's Arrowhead Pharmaceuticals shares are currently valued at $140.24M.

If you're new to stock investing, here's how to buy Arrowhead Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.